Adalimumab eye injections vs under-skin shots for uveitis
Treatments studied
Part of Eyes & vision clinical trials.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-infectious uveitis that affects the back or middle of the eye (not just the front).
- Your uveitis is “active” right now, even though you’ve been on prednisone at least 10 mg/day for at least 2 weeks (or a similar steroid).
- You’ve had a documented good response to steroid tablets in the past.
- If you take prednisone 10 mg or more, your dose has not been changed for the last 14 days.
- Your tuberculosis (TB) test is negative, or if it’s positive you’ve taken anti-TB medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
This study tests whether a lower dose of adalimumab (a biologic medication) can keep controlling chronic non-infectious uveitis (eye inflammation that is not caused by an infection) after it has been well-controlled for a long time. If you have stable eye inflammation and have been on the standard adalimumab dose (40 mg every 2 weeks) for at least 24 weeks, this trial may be suitable for you.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
This study tests whether receiving two YUTIQ injections works better than a sham (fake) treatment for long-lasting inflammation inside the back part of the eye. It is meant to reduce ongoing “posterior segment” inflammation and improve comfort and eye health when prior steroid treatments have helped but the inflammation keeps coming back.
This trial tests a different way of giving a steroid injection for eye swelling (macular edema) caused by uveitis. It is for people whose swelling hasn't improved with a standard steroid injection behind the eye.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.